Dashboard
Manage Tickers

NTRA Natera, Inc.

Nasdaq natera.com


$ 192.54 $ -0.29 (-0.15 %)    

Monday, 27-Oct-2025 18:47:12 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 628.93 $ 10.99 (1.78 %)
DIA $ 475.40 $ 3.14 (0.66 %)
SPY $ 685.52 $ 7.99 (1.18 %)
TLT $ 91.88 $ 0.31 (0.34 %)
GLD $ 367.78 $ -10.51 (-2.78 %)
$ 192.22
$ 194.72
$ 187.24 x 1
$ 198.20 x 50
$ 189.38 - $ 195.44
$ 117.27 - $ 198.99
1,108,907
na
26.38B
$ 1.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-28-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 11-05-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 03-31-2019 10-Q
27 03-15-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-24-2016 12-31-2015 10-K
40 11-13-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

a-glimpse-into-the-expert-outlook-on-natera-through-8-analysts
A Glimpse Into The Expert Outlook On Nater...
10/23/2025 18:00:59

btig-maintains-buy-on-natera-raises-price-target-to-210
BTIG Maintains Buy on Natera, Raises Price...
10/23/2025 17:29:30

BTIG analyst Mark Massaro maintains Natera (NASDAQ:NTRA) with a Buy and raises the price target from $200 to $210.

nateras-signatera-demonstrates-predictive-power-in-imvigor011-guiding-tecentriq-use-for-improved-bladder-cancer-outcomes
Natera's Signatera Demonstrates Predictive...
10/20/2025 06:42:14

Data to be featured in Presidential Symposium at ESMOSignatera™ changes the paradigm by expanding the adjuvant decision window,...

canaccord-genuity-maintains-buy-on-natera-maintains-200-price-target
Canaccord Genuity Maintains Buy on Natera,...
10/14/2025 14:08:29

Canaccord Genuity analyst Kyle Mikson maintains Natera (NASDAQ:NTRA) with a Buy and maintains $200 price target.

heres-how-much-1000-invested-in-natera-5-years-ago-would-be-worth-today
Here's How Much $1000 Invested In Natera 5...
10/13/2025 20:00:40

reported-earlier-natera-showcases-14-esmo-2025-presentations-with-six-oral-sessions-demonstrating-signateras-expanding-role-across-multiple-solid-tumors
Reported Earlier, Natera Showcases 14 ESMO...
10/13/2025 06:28:05

natera-enrolls-over-1600-patients-in-expand-trial
Natera Enrolls Over 1,600 Patients In EXPA...
10/01/2025 12:03:09

natera-announces-publishes-signatera-validation-study-in-testicular-cancer-in-journal-of-clinical-oncology---precision-oncology
Natera Announces Publishes Signatera Valid...
09/30/2025 12:16:47

Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers

heres-how-much-1000-invested-in-natera-5-years-ago-would-be-worth-today
Here's How Much $1000 Invested In Natera 5...
09/24/2025 22:45:22

how-do-investors-really-feel-about-natera
How Do Investors Really Feel About Natera?
09/23/2025 20:00:47

deep-dive-into-natera-stock-analyst-perspectives-6-ratings
Deep Dive Into Natera Stock: Analyst Persp...
09/22/2025 13:01:21

wells-fargo-initiates-coverage-on-natera-with-equal-weight-rating-announces-price-target-of-175
Wells Fargo Initiates Coverage On Natera w...
09/22/2025 12:52:00

Wells Fargo analyst Brandon Couillard initiates coverage on Natera (NASDAQ:NTRA) with a Equal-Weight rating and announces Pr...

if-you-invested-100-in-natera-stock-5-years-ago-you-would-have-this-much-today
If You Invested $100 In Natera Stock 5 Yea...
09/15/2025 22:30:21

neogenomics-gains-unexpected-win-as-court-rejects-natera-claims
NeoGenomics Gains 'Unexpected' Win As Cour...
08/29/2025 17:04:10

NeoGenomics wins a North Carolina court ruling invalidating key Natera patents, clearing the way for its RaDaR ST assay and boo...

natera-patent-claims-against-neogenomics-radar-v11-invalidated-company-weighs-appeal-further-enforcement
Natera Patent Claims Against NeoGenomics' ...
08/29/2025 12:21:27

Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its int...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
08/29/2025 12:07:49

natera-announces-activation-of-nrg-oncology-trial-archer-randomized-phase-iii-study-in-muscle-invasive-bladder-cancer
Natera Announces Activation Of NRG Oncolog...
08/28/2025 12:10:49

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrenceNatera, I...

natera-launches-proprietary-ai-foundation-models-built-on-250000-tumor-exomes-and-1m-plasma-timepoints-to-advance-oncology-diagnostics-and-therapeutics
Natera Launches Proprietary AI Foundation ...
08/22/2025 09:15:38

natera-released-topline-results-from-the-phase-3-imvigor011-trial-in-muscle-invasive-bladder-cancer-showing-that-signatera-positive-patients-treated-with-atezolizumab-tecentriq-had-statistically-significant-and-clinically-meaningful-improvements-in-disease-free-survival-and-overall-survival
Natera Released Topline Results From the P...
08/18/2025 10:07:55

The trial is sponsored by Genentech, a member of the Roche Group. IMvigor011 is the first prospective phase III study in muscle...

stephens--co-reiterates-overweight-on-natera-maintains-183-price-target
Stephens & Co. Reiterates Overweight on Na...
08/15/2025 12:49:26

Stephens & Co. analyst Mason Carrico reiterates Natera (NASDAQ:NTRA) with a Overweight and maintains $183 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION